Lallemand Health Solutions has launched a new contract manufacturing and development platform, Expert’Biome CDMO, which will strengthen its positioning in the microbiome field.
 
With the new platform, the company aims to support partners in developing next-generation strains by offering services like strina research and development, bioprocess scaling, drug manufacturing, and other production steps.
 
“Expert’Biome leverages 90 years of know-how, from research and development to pilot-scale production and commercial manufacturing for microorganisms, and uses cutting-edge technologies and innovative scientific approaches to pioneer next-generation strains,” said Jérôme Panes, president and general manager. “Our manufacturing facilities adhere to the highest quality standards since several decades, including cGMP Pharma for investigational and commercial biological products, internationally recognized accreditations and licenses. We are committed to securing a leading position in this booming market.” These standards are the EU GMP for human medicinal products and human investigational medicinal products.
 
“Laurie Rey, with a PhD in Molecular Biology, has been appointed as head of Expert’Biome business development,” Pane continued. “She will bring her experience, cumulated in the last decade, in partnership development in the life sciences and biotechnology sectors. As the main point of contact for this activity, she will ensure streamlined project execution”.
 
“The microbiome is taking on new significance, as evidenced by increased research and development and commercial success,” said Rey. “Between 2021 and 2023, there has been a 24% increase in ongoing development trials worldwide, along with an 18% increase in countries with products in development targeting the microbiome. Over the past two years, several regulatory approvals have paved the way for next-generation microbiome strains as pontetial drugs to improve well-being in various health areas.”